Publications

Recent Publications

TG-1101 (Ublituximab) References

Lovett-Racke A, Fox E et. al. Placebo controlled, phase 2a multicenter study of ublituximab (UTX), a novel glycoengineered anti-CD20 monoclonal antibody (mAb), in patients with relapsing forms of multiple sclerosis (RMS): 6 months analysis of B cell subsets European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS). 2017-10-27 Abstract

Fox E, et. al. Patient characteristics, safety, and preliminary results of a placebo controlled, phase 2a multicenter study of ublituximab (UTX), a novel glycoengineered anti-CD20 monoclonal antibody (mAb), in patients with relapsing forms of multiple sclerosis European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS). 2017-10-26 Abstract

Inglese M, et. al. Preliminary results of phase 2 multicenter study of ublituximab (UTX), a novel glycoengineered anti-CD20 monoclonal antibody (mAb), in patients with relapsing forms of multiple sclerosis (RMS) demonstrates rapid Gd-enhancing lesions decrease European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS). 2017-10-26 Abstract

Fox E, et. al. Rapid and Robust B Cell Depletion in Preliminary Results of Phase 2 Multicenter Study of Ublituximab (UTX), a Novel Glycoengineered Anti-CD20 Monoclonal Antibody (mAb), in Patients with Relapsing forms of Multiple Sclerosis (RMS) EAN. 2017-06-24 Abstract

Mato A, et. al. Ublituximab and ibrutinib for previously treated genetically high-risk chronic lymphocytic leukemia: Results of the GENUINE Phase 3 study International Congress on Malignant Lymphoma (ICML). 2017-06-16 Abstract 101

Sharman J, et. al. Ublituximab and ibrutinib for previously treated genetically high-risk chronic lymphocytic leukemia: Results of the GENUINE Phase 3 study American Society of Clinical Oncology Annual Meeting (ASCO). 2017-06-03 Abstract 7504

Lovett-Racke A, Fox E et. al. Rapid and Robust B Cell Depletion in Preliminary Results of a Phase 2 Study of Ublituximab, Novel Glycoengineered Anti-CD20 Mab, RMS Patients CMSC. 2017-05-26 Abstract

Lovett-Racke A, Fox E et. al. Preliminary results of Phase 2 Multicenter Study of Ublituximab (UTX), a novel glycoengineered anti-CD20 monoclonal antibody (mAb), in patients with relapsing forms of Multiple Sclerosis (RMS) demonstrates rapid and robust B cell depletion AAN. 2017-04-28 Abstract 3113

Sharman, Burke et. al. Ublituximab (TG-1101), a novel glycoengineered anti-CD20 antibody, in combination with ibrutinib is safe and highly active in patients with relapsed and/or refractory chronic lymphocytic leukaemia: results of a phase 2 trial BJH. 2017-02-21 Abstract

Sawas, O'Connor et. al. A phase 1/2 trial of ublituximab, a novel, glycoengineered anti-CD20 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma or chronic lymphocytic leukaemia previously exposed to rituximab BJH. 2016-12-16 Abstract

Levy M, Mealy M, et. Al. Open Label Safety Study of Ublituximab for the Treatment of Acute Neuromyelitis Optica Relapses European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS). 2016-09-14 Abstract P1195


TGR-1202 References

Nastoupil L, et al. Chemo-free triplet combination of TGR-1202, ublituximab, and ibrutinib is well tolerated and highly active in patients with advanced CLL and NHL Congress of the European Hematology Association (EHA). 2017-06-24 Abstract

Lunning M, et. al. Combination of TGR-1202, Ublituximab, and bendamustine is safe and highly active in patients with advanced DLBCL and follicular lymphoma Congress of the European Hematology Association (EHA). 2017-06-24 Abstract

Nastoupil L, et al. Chemo-free triplet combination of TGR-1202, ublituximab, and ibrutinib is well tolerated and highly active in patients with advanced CLL and NHL International Congress on Malignant Lymphoma (ICML). 2017-06-16 Abstract 102

Lunning M, et. al. Combination of TGR-1202, Ublituximab, and Bendamustine is safe and highly active in patients with advanced DLBCL and Follicular Lymphoma International Congress on Malignant Lymphoma (ICML). 2017-06-15 Abstract 277

Davids M, et al. TG Therapeutics, Inc. Announces Follow-Up Data for Combination of TGR-1202 (umbralisib) plus Ibrutinib in Patients with Relapsed or Refractory CLL and MCL at the 14th International Conference on Malignant Lymphoma International Congress on Malignant Lymphoma (ICML). 2017-06-14 Abstract 040

Nastoupil L, et al. Tolerability and activity of chemo-free triplet combination of TGR-1202, ublituximab, and ibrutinib in patients with advanced CLL and NHL American Society of Clinical Oncology Annual Meeting (ASCO). 2017-06-05 Abstract 7511

Dorsey, Mato, et. al. KI intolerance study: A phase 2 study to assess the safety and efficacy of TGR-1202 in pts with chronic lymphocytic leukemia (CLL) who are intolerant to prior BTK or PI3K-delta inhibitor therapy American Society of Clinical Oncology Annual Meeting (ASCO). 2017-06-05 Abstract TPS7569

Pinilla-Ibarz, et. al. TGR-1202– A novel PI3K-delta inhibitor that differentially regulates T cells in CLL iwCLL. 2017-05-15 Abstract

Davids M, et al. TGR-1202 in Combination with Ibrutinib in Patients with Relapsed or Refractory CLL: Updated Results of a Multicenter Phase I/Ib Study iwCLL. 2017-05-15 Abstract

Lunning M, et. al. Combination of Ublituximab, TGR-1202 and Bendamustine Demonstrates Significant Activity in Patients with Advanced DLBCL and Follicular Lymphoma. American Society of Hematology Annual Meeting (ASH). 2016-12-05 Abstract 4197

Ramchandran et al. A Phase I Trial of TGR-1202, a Next Generation Once Daily PI3K Delta Inhibitor, in Combination with Brentuximab Vedotin, in Patients with Relapsed/Refractory Hodgkins Lymphoma American Society of Hematology Annual Meeting (ASH). 2016-12-05 Abstract 4146

Moyo et al. Preliminary Results from a Phase I Dose Escalation Trial of Ruxolitinib and the PI3K Delta Inhibitor TGR-1202 in Myelofibrosis. American Society of Hematology Annual Meeting (ASH). 2016-12-05 Abstract 1125

Davids M, et al. TGR-1202 in Combination with Ibrutinib in Patients with Relapsed or Refractory CLL or MCL: Preliminary Results of a Multicenter Phase I/Ib Study. American Society of Hematology Annual Meeting (ASH). 2016-12-05 Abstract

Maharaj, et. al. Modulation of T cell Compartment in a Preclinical CLL Murine Model by a Selective PI3K delta inhibitor, TGR-1202. American Society of Hematology Annual Meeting (ASH). 2016-12-04 Abstract

Deng C, et.al. Silencing cMyc Translation as a Therapeutic Strategy Through Targeting PI3K Delta and CK1 Epsilon in Hematological Malignancies. American Society of Hematology Annual Meeting (ASH). 2016-12-04 Abstract

Deng C, O'Connor O, et. al. Silencing c-Myc Translation as a Therapeutic Strategy through Targeting PI3K Delta and CK1 Epsilon in Hematological Malignancies Blood. 2016-10-27 Abstract


anti PD-L1 References

Marasco W, Gorelik L, et al Preclinical Characterization of a Fully Human lgG1 Anti-PD-L1 mab CK-301 American Association for Cancer Research Annual Meeting (AACR). 2017-04-04 Abstract


Sort By: Sort Direction:

Filter By: Year Drug Conference

Date Drug Conference Lead Author Title Abstract #
12/07/2010 TG-1101 American Society of Hematology Annual Meeting (ASH) Cartron G, Cazin B, et. al. A Phase I study of LFB-R603, a Novel Anti-CD20 Antibody, in Patients with Relapsed Chronic Lymphocytic Leukemia. 2447
12/13/2011 TG-1101 American Society of Hematology Annual Meeting (ASH) Bellon A, Salcedo M, et. al. Comparison of Cell Lysis Mediated by LFB-R603 with That Mediated by Ofatumumab Against Cells Expressing Low Levels of CD20. 3913
12/13/2011 TG-1101 American Society of Hematology Annual Meeting (ASH) Cazin B, Coiffier B, Cartron G, et. al. Multicentre Phase I Study with an 8-Dose Regimen of Single Agent Anti-CD20 Monoclonal Antibody LFB-R603 in Patients with Relapsed Chronic Lymphocytic Leukemia (CLL). 2862
12/13/2011 TG-1101 American Society of Hematology Annual Meeting (ASH) Echelard Y, Meade HM, et. al. TG20, a Transgenically-Derived Anti-CD20 Monoclonal Antibody, Exhibits Enhanced Cytotoxicity Against Cells with Low Levels of CD20. 2730
12/13/2011 TG-1101 American Society of Hematology Annual Meeting (ASH) Tourais Esteves I, Fournès B, et. al. LFB-R603, a Third-Generation Monoclonal Anti-CD20 Antibody Displays An Additive Antitumor Activity with Antileukemic Chemotherapeutic Agents in Mouse Xenograft Models. 1660
04/04/2012 TGR-1202 American Association for Cancer Research Annual Meeting (AACR) Vakkalanka S, Viswanadha S, et. al. Inhibition of PI3Kd kinase by a selective small molecule inhibitor suppresses B-cell proliferation and leukemic cell growth. 3741
12/11/2012 TG-1101 American Society of Hematology Annual Meeting (ASH) Barth M, Czuczman M, et. al. Ublituximab (TGTX-1101), A Novel Anti-CD20 Monoclonal Antibody (mAb), Demonstrates Activity in Rituximab-sensitive and Rituximab–resistant B Non-Hodgkin Lymphoma (B-NHL) Pre-clinical In Vitro and In Vivo Models. 2756
12/11/2012 TG-1101 American Society of Hematology Annual Meeting (ASH) Donnou S, Fisson S, et. al. Ublituximab (TGTX-1101), a Novel, Third-Generation Anti-CD20 Antibody Demonstrates Enhanced Antitumor Activity Compared to Rituximab in Primary CNS and Intraocular Lymphoma Murine Models. 2755
12/11/2012 TG-1101 American Society of Hematology Annual Meeting (ASH) Le Garff-Tavernier M, Leblond V, et. al. Ublituximab, an Optimized Anti-CD20 Monoclonal Antibody, Demonstrates Greater NK-Mediated ADCC Than Rituximab in Waldenstrom's Macroglobulinemia Patients Supporting a Therapeutic Strategy with Ublituximab. 1654
12/11/2012 TGR-1202 American Society of Hematology Annual Meeting (ASH) Savona M, Vakkalanka S, et. al. Suppresses AML and ALL Cells Via Selective Inhibition of PI3K-delta Kinase. 2610
12/11/2012 TGR-1202 American Society of Hematology Annual Meeting (ASH) Friedman D, Lanasa M, Weinberg B,et. al. Comparison of the PI3K-delta Inhibitors TGR1202 and GS-1101 in Inducing Cytotoxicity and Inhibiting Phosphorylation of Akt in CLL Cells in Vitro. 3914
12/11/2012 TGR-1202 American Society of Hematology Annual Meeting (ASH) Changchun D, O'Connor O, et. al. Novel PI3K Inhibitors Demonstrated Marked Cytotoxicity in T Cell Lymphoma Models, Caused Apoptosis and Were Synergistic with A Novel Anti-CD20 Monoclonal Antibody Ublituximab in B Cell Lymphoma Models. 3725
06/01/2013 TGR-1202 International Congress on Malignant Lymphoma (ICML) Deng, Changchun June 2013
06/02/2013 TG-1101 American Society of Clinical Oncology Annual Meeting (ASCO) Changchun D, O'Connor O, et. al. A Phase I Dose-Escalation Trial of Ublituximab (TG-1101), a Novel Anti-CD20 Monoclonal Antibody (mAb) for Rituximab Relapsed and/or Refractory C-Cell Lymphoma Patients. 8575
06/14/2013 TG-1101 Congress of the European Hematology Association (EHA) Cazin B, Ribrag V, et. al. Final Results of a Multicenter Phase Ib Single Agent Study with the Novel Anti-CD20 Monoclonal Antibody Ublituximab (TG-1101) in Patients with Relapsed Chronic Lymphocytic Leukemia (CLL). 111
06/14/2013 TG-1101 Congress of the European Hematology Association (EHA) Changchun D, O'Connor O, et. al. Ublituximab (TG-1101), a Novel Anti-CD20 Monoclonal for Rituximab Relapsed/Refractory B-cell Malignancies. 325
06/14/2013 TGR-1202 Congress of the European Hematology Association (EHA) Vakkalanka S, Viswanadha S, et. al. A Novel, PI3K-Delta Specific Inhibitor in Multiple Myeloma. 753
09/09/2013 TGR-1202 American Association for Cancer Research Annual Meeting (AACR) Friedman D, Lanasa M, et. al. The PI3k-delta inhibitor TGR-1202 induces cytotoxicity and inhibits phosphorylation of AKT in 17p deleted and non-17p deleted CLL cells in vitro. Poster
12/10/2013 TGR-1202 American Society of Hematology Annual Meeting (ASH) Deng C, O'Connor O, et. al. The PI3K Delta Inhibitor TGR-1202 and Proteasome Inhibitor Carfilzomib are Highly Synergistic in Killing Human B- and T-Cell Lymphoma Cells. 4421
12/10/2013 TGR-1202 American Society of Hematology Annual Meeting (ASH) Locatelli S, and Carlo-Stella C, et. al. The PI3K-d Inhibitor TGR-1202 in Combination with Brentuximab Vedotin (SGN-35) Synergistically Induces G2/M Phase Arrest and Cell Death Via Inhibition Of Tubulin Polymerization in Hodgkin Lymphoma Cell Lines. 1835
12/10/2013 TGR-1202 American Society of Hematology Annual Meeting (ASH) Torre C, Lonial S, et. al. Combined Carfilzomib and Selective PI3K-d Inhibition (TGR-1202) Results in Enhanced Myeloma Cell Apoptosis. 3224
12/10/2013 TGR-1202 American Society of Hematology Annual Meeting (ASH) Savona M, Patel M, et. al. A Phase I Dose Escalation Study of TGR-1202, a Novel PI3K-d Inhibitor, For Patients with Relapsed or Refractory Hematologic Malignancies. 4373
04/09/2014 TGR-1202 American Association for Cancer Research Annual Meeting (AACR) Friedman D, Lanasa M, et. al. The PI3K Delta Inhibitor TGR-1202 Induces Cytotoxicity and Inhibits Phosphorylation of AKT in 17p Deleted and Non-17p Deleted CLL Cells in Vitro. 4518
04/09/2014 TGR-1202 American Association for Cancer Research Annual Meeting (AACR) Locatelli S, Carlo-Stella C, et. al. The PI3K Delta Inhibitor TGR-1202 In Combination with Brentuximab Vedotin (SGN-35) Synergistically Induces G2/M Phase Arrest and Cell Death Via Inhibition of Tubulin Polymerization in Hodgkin Lymphoma Cell Lines. 4711
05/30/2014 TG-1101 American Society of Clinical Oncology Annual Meeting (ASCO) Changchun D, O'Connor O, et. al. A Phase I Trial of Ublituximab (TG-1101), a Novel Anti-CD20 Monoclonal Antibody (MAB) in B-Cell Lymphoma Patients with Prior Exposure to Rituximab. 8524
05/30/2014 TGR-1202 American Society of Clinical Oncology Annual Meeting (ASCO) Burris H, Flinn I, et. al. Activity of TGR-1202, a Novel Once-Daily Pi3K Delta Inhibitor, in Patients with Relapsed or Refractory Hematologic Malignancies. 2513
06/13/2014 TG-1101 Congress of the European Hematology Association (EHA) O'Connor O, Farber C, et. al. Ublituximab (TG-1101), A Novel Anti-CD20 Monoclonal Antibody for Rituximab Relapsed/Refractory B-Cell Malignancies. 444
06/13/2014 TG-1101 Congress of the European Hematology Association (EHA) Sharman J, O'Connor O, et. al. Ublituximab (TG-1101), A Novel Glycoenginereed Anti-CD20 mAb, in Combination with Ibrutinib in Patients with CLL and MCL; Results of an Ongoing Phase II Trial. 880
06/13/2014 TGR-1202 Congress of the European Hematology Association (EHA) Burris H, Flinn I, et. al. a Novel Once-Daily Pi3K Delta Inhibitor, in Patients with Relapsed or Refractory Hematologic Malignancies. 250
07/21/2014 TG-1101 Pan Pacific Lymphoma Conference Lunning M, O'Brien S, et. al. A Phase I Trial of Ublituximab, A Novel Glycoengineered Anti-CD20 mAb, In Combination With TGR-1202, A Next Generation PI3K Delta Inhibitor, In Patients With Chronic Lymphocytic Leukemia And Non-Hodgkin's Lymphoma. July 21, 2014
12/09/2014 TG-1101 American Society of Hematology Annual Meeting (ASH) Lunning M, O'Brien S, et. al. Ublituximab, a Novel Glycoengineered Anti-CD20 Monoclonal Antibody (mAb), in Combination with TGR-1202, a Next Generation Once Daily PI3K Delta Inhibitor, Demonstrate Activity in Heavily Pre-Treated and High-Risk Chronic Lymphocytic Leukemia (CLL) and B-Cell Lymphoma. Dec 6-9, 2014
12/09/2014 TG-1101 American Society of Hematology Annual Meeting (ASH) Sharman J, Greenwald D, et.al. Ublituximab (TG-1101) a Novel Glycoengineered Anti-CD20 Monoclonal Antibody, in Combination with Ibrutinib is Highly Active in Patients with Relapsed and/or Refractory CLL and MCL: Results of a Phase II Trial. 4679
12/09/2014 TGR-1202 American Society of Hematology Annual Meeting (ASH) Burris H, Flinn I, et. al. a Novel Once Daily Pi3K Delta Inhibitor, Demonstrates Clinical Activity with a Favorable Safety Profile, Lacking Hepatotoxicity, in Patients with Chronic Lymphocytic Leukemia and B-Cell Lymphoma. 1984
12/09/2014 TGR-1202 American Society of Hematology Annual Meeting (ASH) Deng C, O'Connor O, et. al. Complementary Targeting of PI3K and the Proteasome Causes Potent Inhibition of mTORC1 and NF-kappaB in Models of B- and T-Cell Lymphoma. 1770
12/09/2014 TGR-1202 American Society of Hematology Annual Meeting (ASH) Locatelli, et. al. The PI3K-delta Inhibitor TGR-1202 in Combination with Brentuximab Vedotin (SGN-35) Synergistically Inhibits Tubulin Polymerization and Exerts Potent Antitumor Effects in NOD/SCID Mice with Hodgkin Lymphoma Cell Line Xenografts. 4486
04/18/2015 IRAK4 American Association for Cancer Research Annual Meeting (AACR) Vajda E, Marschke K, et. al. IRAK4 inhibitors display synergistic activity when combined with BTK or PI3K inhibitors in B-cell lymphomas. #785
06/02/2015 TG-1101 American Society of Clinical Oncology Annual Meeting (ASCO) Fowler N, O'Brien S, et al. Safety and Activity of the Chemotherapy-free Triplet of Ublituximab, TGR-1202 and ibrutinib in Relapsed B-cell Malignancies. June 2,2015
06/02/2015 TG-1101 American Society of Clinical Oncology Annual Meeting (ASCO) Lunning M, O'Brien S, et. al. Ubliuximab +TGR-1202 Demonstrates Activity and Favorable Safety Profile in Relapsed/Refractory B-Cell NHL and High-Risk CLL. June 2,2015
06/02/2015 TGR-1202 American Society of Clinical Oncology Annual Meeting (ASCO) Burris H, Flinn I, et. al. Clinical Activity and Safety Profile of TGR-1202, a Novel Once Daily Pi3k Delta Inhibitor, in Patients with CLL and B-Cell Lymphoma. June 2, 2015
06/14/2015 TG-1101 Congress of the European Hematology Association (EHA) Lunning M, et. al. Ublituximab + TGR-1202 Demonstrates Activity and Favorable Safety Profile in Relapsed/Refractory B-Cell NHL and High-Risk CLL. P327
06/14/2015 TGR-1202 Congress of the European Hematology Association (EHA) O'Connor, et. al. a Novel Once Daily PI3K-Delta Inhibitor, Demonstrates Clinical Activity with a Favorable Safety Profile, Lacking Hepatotoxicity, in Patients with CLL and B-Cell Lymphoma. S432
06/20/2015 TG-1101 International Congress on Malignant Lymphoma (ICML) Lunning M, et. al. Ublituximab + TGR-1202 Demonstrates Activity and Favorable Safety Profile in Relapsed/Refractory B-Cell NHL and High-Risk CLL. 284
06/20/2015 TG-1101 International Congress on Malignant Lymphoma (ICML) Burke J, et. al. Ublituximab (TG-1101), a Novel Glycoengineered Anti-CD20 MAB, in Combination with Ibrutinib Achieves 95% ORR in Patients with High-Risk Relapsed/Refractory CLL. 105
06/20/2015 TG-1101 International Congress on Malignant Lymphoma (ICML) Nastoupil L, et al. The Chemotherapy-Free Triplet of Ublituximab, TGR-1202, and Ibrutinib is Safe and Highly Active in Relapsed B-Cell Malignancies. 106
06/20/2015 TGR-1202 International Congress on Malignant Lymphoma (ICML) O'Connor, et. al. a Novel Once Daily PI3K-Delta Inhibitor, Demonstrates Clinical Activity with a Favorable Safety Profile, Lacking Hepatotoxicity in Patients with CLL and B-Cell Lymphoma. 038
09/09/2015 TGR-1202 (iwCLL) O'Brien, et. al. a Novel Once Daily PI3K-Delta Inhibitor, Demonstrates Clinical Activity with a Favorable& Differentiated Safety Profile as a Single Agent and in Combination with a Novel Glyocengineered anti-CD20 mAb, Ublituximab in Patients with Rel/Ref CLL. September 9
12/05/2015 TG-1101 American Society of Hematology Annual Meeting (ASH) SharmanJ, et. Al. Ublituximab (TG-1101), a Novel Glycoengineered Anti-CD20 Monoclonal Antibody, in Combination with Ibrutinib is Highly Active in Patients with Relapsed and/or Refractory Mantle Cell Lymphoma: Results of a Phase II Trial. 3980
12/08/2015 TG-1101 American Society of Hematology Annual Meeting (ASH) Lunning M, et. al. Ublituximab + TGR-1202 Demonstrates Activity and a Favorable Safety Profile in Relapsed/Refractory B-Cell NHL and High-Risk CLL: Phase I Results. 1538
12/08/2015 TG-1101 American Society of Hematology Annual Meeting (ASH) Sharman J, et. al. Ublituximab (TG-1101), a Novel Glycoengineered Anti-CD20 Monoclonal Antibody, in Combination with Ibrutinib is Highly Active in Patients with Relapsed and/or Refractory Mantle Cell Lymphoma: Results of a Phase II Trial. 3980
12/08/2015 TGR-1202 American Society of Hematology Annual Meeting (ASH) Deng C, et.al. Disruption of the mTOR-eIF4F Axis By Selectively Targeting PI3Kdelta and Proteasome Potently Inhibits Cap Dependent Translation of c-Myc in Aggressive Lymphomas. December 5 - 8, 2015
12/08/2015 TGR-1202 American Society of Hematology Annual Meeting (ASH) Mahadevan D, et. al. a Next Generation Once Daily PI3K-Delta Inhibitor in Combination with Obinutuzumab Plus Chlorambucil, in Patients with Chronic Lymphocytic Leukemia. 2942
12/08/2015 TGR-1202 American Society of Hematology Annual Meeting (ASH) O'Connor O, et. al. a Novel Once Daily PI3K- Delta Inhibitor, in Patients with CLL and B-Cell Lymphoma. 4154
04/16/2016 TGR-1202 American Association for Cancer Research Annual Meeting (AACR) Pinilla-Ibarz, et. al. Differential Regulation of Human T cells by TGR-1202, A Novel PI3K-delta Inhibitor.
06/01/2016 TGR-1202 Congress of the European Hematology Association (EHA) O'Connor O, et. al. Long-term follow-up of PI3K delta inhibitor TGR-1202 demonstrates safety and high response rates in NHL: INtegrated Analysi sof TGR-1202 monotherapy and combined with ublituximab.
06/01/2016 TGR-1202 Congress of the European Hematology Association (EHA) Mato A, et. al. Long-term follow-up of the PI3k delta inhibitor TGR-1202 demonstrates a differentiated safety profile and high response rates in CLL: Integrated-analysis of TGR-1202 monotherapy and commbined with ublituximab.
06/01/2016 TGR-1202 Congress of the European Hematology Association (EHA) Davids M, et al. Preliminary Results of a Phase I/Ib Study of Ibrutinib in Combination with TGR-1202 in Patients with Relapsed/Refractory CLL or MCL.
06/03/2016 TGR-1202 American Society of Clinical Oncology Annual Meeting (ASCO) Burris H, Flinn I, et. al. Long-term follow-up of the PI3K delta inhibitor TGR-1202 demonstrates a differentiated safety profile and high response rates in CLL and NHL: Integrated-analysis of TGR-1202 monotherapy and combined with ublituximab. #7512